Laboratory-Based Surveillance for Rotavirus—United States, July 1996-June 1997 | Gastroenterology | JAMA | JAMA Network
[Skip to Navigation]
Citations 0
News From the Centers for Disease Control and Prevention
January 21, 1998

Laboratory-Based Surveillance for Rotavirus—United States, July 1996-June 1997

JAMA. 1998;279(3):192. doi:10.1001/jama.279.3.192-JWR0121-5-1

MMWR. 1997;46:1092-1094

1 figure omitted

ROTAVIRUS INFECTIONS are the most common cause of severe gastroenteritis among infants and young children worldwide.1,2 Each year in the United States, rotavirus infections account for an estimated 3.5 million cases of diarrhea, 500,000 physician visits, 50,000 hospitalizations, and 20 deaths among children aged <5 years.2 In addition, rotavirus accounts for 30%-50% of U.S. hospitalizations for diarrhea among children aged <5 years, including approximately 50% of hospitalizations for diarrhea during annual seasonal peaks, and is an important cause of nosocomial gastroenteritis.3 Rotavirus activity in the United States is monitored by the National Respiratory and Enteric Virus Surveillance System (NREVSS), a voluntary, laboratory-based system.4 This report summarizes surveillance from NREVSS during July 1996-June 1997.

From July 1996 through June 1997, a total of 69 laboratories in 42 states participated in NREVSS and reported weekly to CDC the number of stool specimens tested for rotavirus by antigen-detection and electron microscopy methods and the number of positive results. Of 23,199 fecal specimens examined, 6183 (27%) were positive for rotavirus. Timing of rotavirus activity varied by geographic location; peak activity occurred first in the Southwest in November 1996 and last in the Northeast in April and May.* Data from Alaska and Hawaii were not available.

Reported by:

MT Bosley, Georgia Institute of Technology, Atlanta, Georgia. National Respiratory and Enteric Virus Surveillance System collaborating laboratories; Viral Gastroenteritis Section, Respiratory and Enteric Viruses Br, and Office of the Director, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

CDC Editorial Note:

Seasonal increases in rotaviral diarrhea occur annually throughout the United States, and the temporal and geographic trends during the July 1996-June 1997 reporting period were similar to trends in previous years.4 The timing of rotavirus activity is sequential, beginning first in the Southwest in autumn and ending in the Northeast in mid- to late-spring; however, the time of peak activity in the Pacific Northwest is more variable than in other regions, occurring from winter to late spring. The reasons for the sequential pattern in rotavirus activity across the United States are unknown; it is not explained by a sequential introduction and diffusion of new rotavirus strains because rotavirus activity often is caused by a mixture of common strains that may vary between cities.5,6

NREVSS is the largest, nationally representative system for surveillance of rotavirus infections in the United States.4 This system uses an automated telephone reporting system to transmit reports from participating laboratories to CDC and allows timely analysis of rotavirus trends. Limitations of the system are that (1) some regions of the country are sparsely represented, and data are not reported from Alaska and Hawaii; (2) demographic or clinical data are not collected; and (3) specimens are not routinely submitted for confirmation or strain characterization.

The large disease burden and high cost associated with rotavirus infections in the United States have been the impetus for development of rotavirus vaccines. Two human-animal reassortant vaccines have been found to be safe and effective,7-10 and a vaccine is under review for licensure for use among U.S. children; both the Advisory Committee of Immunization Practices and the Committee on Infectious Diseases of the American Academy of Pediatrics are considering recommendations for the use of the vaccine in children.

The prospect of a program for childhood vaccination against rotavirus in the United States highlights the need for continued surveillance for this infection. Laboratory-based surveillance has helped characterize the spatiotemporal trends of rotavirus infections and provides a baseline for monitoring changes in the epidemiology of these infections following vaccine introduction. Efforts to enhance rotavirus surveillance should include surveillance for rotavirus-associated diarrheal outcomes, particularly hospitalizations, and for rotavirus strains. These measures also will assist in assessing vaccine program effectiveness and the potential emergence of novel or unusual rotaviruses.

*A short animation showing rotavirus activity by week is available on the World-Wide Web at
de Zoysa  IFeachem  RG Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization.  Bull World Health Organ. 1985;63569- 83Google Scholar
Glass  RIKilgore  PEHolman  RC  et al.  The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.  J Infect Dis 1996;174 ((suppl 1)) S5- S11Google ScholarCrossref
Matson  DOEstes  MK Impact of rotavirus infection at a large pediatric hospital.  J Infect Dis. 1990;162598- 604Google ScholarCrossref
Tvrvk  TJKilgore  PEClarke  MJHolman  RCBresee  JSGlass  RI Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991-1996.  Pediatr Infect Dis J. 1997;16941- 6Google ScholarCrossref
Gouvea  VHo  M-SGlass  R  et al.  Serotypes and electropherotypes of human rotavirus in the USA: 1987-1989.  J Infect Dis. 1990;162362- 7Google ScholarCrossref
Matson  DOEstes  MKBurns  JWGreenberg  HBTaniguchi  KUrasawa  S Serotype variation of human group A rotaviruses in two regions of the USA.  J Infect Dis. 1990;162605- 14Google ScholarCrossref
Clark  HFOffit  PAEllis  RW  et al.  The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.  J Infect Dis 1996;174 ((suppl 1)) S73- S80Google ScholarCrossref
Kapikian  AZHoshino  YChanock  RMPerez-Schael  I Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.  J Infect Dis 1996;174 ((suppl 1)) S65- S72Google ScholarCrossref
Perez-Schael  IGuntiqas  MJPerez  M  et al.  Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.  N Engl J Med. 1997;3371181- 7Google ScholarCrossref
Joensuu  JKoskenniemi  EPang  X-LVesikari  T Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.  Lancet. 1997;3501205- 9Google ScholarCrossref